Critical Survey: BioDelivery Sciences International (BDSI) versus The Competition

BioDelivery Sciences International (NASDAQ: BDSI) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare BioDelivery Sciences International to related businesses based on the strength of its earnings, risk, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Valuation & Earnings

This table compares BioDelivery Sciences International and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
BioDelivery Sciences International $44.33 million -$31.81 million -10.54
BioDelivery Sciences International Competitors $8.20 billion $2.68 billion -0.84

BioDelivery Sciences International’s peers have higher revenue and earnings than BioDelivery Sciences International. BioDelivery Sciences International is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

41.9% of BioDelivery Sciences International shares are owned by institutional investors. Comparatively, 43.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 9.0% of BioDelivery Sciences International shares are owned by company insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for BioDelivery Sciences International and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioDelivery Sciences International 0 1 5 0 2.83
BioDelivery Sciences International Competitors 835 3744 6770 185 2.55

BioDelivery Sciences International presently has a consensus target price of $4.50, suggesting a potential upside of 52.54%. As a group, “Pharmaceuticals” companies have a potential upside of 28.24%. Given BioDelivery Sciences International’s stronger consensus rating and higher probable upside, equities analysts clearly believe BioDelivery Sciences International is more favorable than its peers.

Volatility and Risk

BioDelivery Sciences International has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, BioDelivery Sciences International’s peers have a beta of 0.90, indicating that their average share price is 10% less volatile than the S&P 500.

Profitability

This table compares BioDelivery Sciences International and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioDelivery Sciences International 3.34% 14.64% 1.90%
BioDelivery Sciences International Competitors -2,859.67% -63.49% -9.24%

Summary

BioDelivery Sciences International beats its peers on 7 of the 12 factors compared.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply